Mesoblast Limited files as an Australian foreign private issuer, and its SEC reports document ASX announcements for its ADR-listed securities. Form 6-K reports incorporate Appendix 4C activity reports, press releases and R&D materials covering Ryoncil commercialization, operating cash spend, clinical programs for rexlemestrocel-L and Ryoncil, FDA regulatory updates and the company’s mesenchymal lineage cell therapy platform.
The filing record also documents capital-structure and governance matters through ASX appendices for proposed and quoted securities, unquoted equity securities, cessation of securities and changes in director interests. These disclosures connect Mesoblast’s public reporting to product revenue, pipeline development, equity issuance and foreign-issuer compliance under Form 20-F reporting.
Mesoblast Limited announced board changes, including William Burns’s planned retirement at the Company’s 2026 Annual General Meeting after 12 years on the Board. Jane Bell AM, who has been co-chair of the Nomination and Remuneration Committee with Burns since April 2026, will take over as chair. Dr Philip Krause ceased to be a director on October 31, 2026, after serving since 2022; the company said he provided regulatory and clinical development expertise as a board member and consultant.
Mesoblast plans to recruit and appoint new directors with U.S. and global commercial expertise in the biotechnology and pharmaceutical sectors. Krause’s final director interest notice lists 28,750 American Depository Shares and 3,385,000 options among securities for which he was the registered holder. Chair Philip Facchina described Mesoblast as a revenue-generating commercial enterprise following Ryoncil’s launch in the United States.
Mesoblast Limited reported first-quarter FY2027 RYONCIL net revenue of US$28 million, up 44% from the prior-year period; management’s initial analysis is subject to completion of financial closing procedures and audit. Net operating cash spend was US$2.1 million versus US$14.9 million a year earlier, an 86% improvement. Cash and cash equivalents were US$98.545 million at September 30, 2026, and estimated funding available was 46.3 quarters.
Mesoblast completed treatment of all enrolled patients in the expanded 350-patient Phase 3 trial of rexlemestrocel-L for chronic inflammatory low back pain; the 12-month durable pain-reduction endpoint is expected to read out next year. The FDA confirmed that a BLA filing may proceed for rexlemestrocel-L to treat life-threatening gastrointestinal bleeding in end-stage heart failure patients being kept alive by an LVAD; formal meeting minutes are expected shortly. The adult SR-aGvHD RYONCIL registration trial has begun enrolling, and the FDA approved an additional potency assay for RYONCIL manufacturing. Mesoblast had drawn US$125 million under a five-year credit-line facility.
Mesoblast Limited (MESO) reported first-fiscal-quarter 2026 Ryoncil net revenue of US$28 million, up 44% from US$19 million in the prior-year period. Net operational cash spend was US$2.3 million, an 85% improvement from US$14.9 million, and the company had a cash position of US$99 million as of September 30, 2026.
September had the highest monthly number of new patient starts, following expected seasonality from summer recess-related treatment scheduling in July and August. Mesoblast said it plans to increase Ryoncil penetration and adoption across 54 onboarded sites. The results are based on management’s preliminary estimates and remain subject to completion of customary closing and audit procedures.
Ryoncil is the first mesenchymal stromal cell product approved by the FDA for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease.
Mesoblast Limited (MESO) reported that on October 14, 2026, it filed three announcements with the Australian Securities Exchange: a notification of cessation of securities, a notification of issue, conversion or payment up of unquoted equity securities, and an application for quotation of securities.
Mesoblast Limited reported FY2026 revenue of US$120.3 million, compared with US$17.2 million in FY2025. RYONCIL generated US$115.2 million in net product sales in its first full fiscal year of U.S. commercialization, and gross profit was approximately US$104 million.
Net operating cash usage was US$43.8 million, versus US$50.0 million in the prior year, and cash and cash equivalents were US$102.9 million as of June 30, 2026. Mesoblast drew the full US$125.0 million five-year credit facility in two tranches to extinguish existing debt. The facility is secured by TEMCELL royalties, carries a fixed 8.00% annual rate, and has an interest-only period through December 2030.
The adult SR-aGvHD Phase 3 registration trial began enrolling, while the pivotal rexlemestrocel-L Phase 3 chronic low back pain trial completed treatment of 350 patients. Mesoblast said it looks forward to reading out clinical endpoints during the second half of calendar 2027.
Mesoblast Limited (MESO) received FDA approval to implement its T-cell Proliferation Inhibition BioAssay (TIBA) for release and stability monitoring of all new commercial RYONCIL product lots. TIBA will be used in a batch-release matrix alongside the existing IL-2Rα inhibition and Cell Adhesion and Proliferation (CAP) assays. Mesoblast said the assay will provide sensitivity to detect potency shifts that could arise from manufacturing-process changes or production at new facilities.
RYONCIL is approved for steroid-refractory acute graft versus host disease in patients aged 2 months or older. Mesoblast describes it as the first industrially manufactured allogeneic MSC product approved by the FDA for any indication.
Mesoblast Limited (MESO) reported a transformational FY2026 as it transitioned into a commercial-stage company driven by the first full year of U.S. sales of RYONCIL. Total revenue rose to US$120.3 million, up sharply from US$17.2 million, with RYONCIL net product sales contributing US$115.2 million after a 13.4% gross-to-net adjustment.
Reported gross profit was US$103.6 million, and gross profit excluding amortization increased to US$109.7 million versus US$16.0 million a year earlier. Mesoblast continued to invest heavily, with research and development expenses of US$97.5 million and selling, general and administrative costs of US$57.3 million reflecting the RYONCIL launch and Phase 3 programs. The net loss narrowed by 44% to US$57.5 million, and operating cash outflow improved to US$43.8 million.
Cash and cash equivalents at June 30, 2026 were US$102.9 million, and the company entered a US$125 million five-year non-dilutive credit facility that replaced higher-cost debt. Operationally, Mesoblast completed treatment of 350 patients in its Phase 3 chronic low back pain trial of rexlemestrocel-L, advanced a registration trial for adult SR-aGvHD, and gained IND clearance for a Phase 3 trial in pediatric Duchenne muscular dystrophy.
Mesoblast Limited (MESO) files its annual report detailing the first full year of commercialization of Ryoncil®, its FDA‑approved mesenchymal stromal cell therapy for pediatric steroid‑refractory acute graft‑versus‑host disease in the United States. Ryoncil® was launched in March 2025 and generated $115.2 million in net product sales for the year ended June 30, 2026.
The company remains loss‑making, reporting a net loss of $57.5 million and accumulated losses of $1,068.4 million since inception. As of June 30, 2026, Mesoblast held $102.9 million in cash and cash equivalents and used $43.8 million of net cash in operating activities during the year.
In December 2025 Mesoblast refinanced existing borrowings with a $125.0 million five‑year non‑dilutive credit line secured by TEMCELL® royalties, bearing fixed 8.00% interest and interest‑only payments through December 2030. Management expects current cash plus Ryoncil® cash flows to fund forecast operating usage for the next 12 months, but discloses that failure to secure adequate funding or partnerships beyond that period could jeopardize its ability to continue as a going concern.
Mesoblast Limited (MESO) reported to U.S. investors that it has issued unquoted options to a director under its employee incentive scheme. On 19 August 2026, key management personnel Philip R. Krause received 875,000 MSBAI options, issued for nil consideration, pursuant to shareholder approval at the 2025 AGM.
Following this grant, Krause holds 3,385,000 options and 28,750 American Depositary Shares. Overall capital now includes 1,298,748,110 ordinary fully paid shares and 89,890,943 MSBAI options on issue, along with several unquoted warrant classes. The options were issued under Listing Rule 7.2 exception 13.
Mesoblast Limited (MESO) reports that it will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast is scheduled for 6:30 p.m. EDT on August 26, 2026 (8:30 a.m. AEST on August 27, 2026) and will be accessible via the company’s investor relations site.
Mesoblast describes itself as a global leader in developing allogeneic (off‑the‑shelf) cellular medicines for severe inflammatory conditions. Its product Ryoncil (remestemcel-L-rknd) is described as the first FDA‑approved mesenchymal stromal cell therapy, indicated for steroid‑refractory acute graft versus host disease in pediatric patients 2 months and older, with additional indications and pipeline programs under development.